2
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
31
Recurrence
5
Hematologic Neoplasms
2
Waldenstrom Macroglobulinemia
1
Neoplasm, Residual
1
Myasthenia Gravis
1
Leukemia, Plasma Cell
1
Infections
1
Immunoglobulin Light-chain Amyloidosis
1
Cytokine Release Syndrome
1
Interventions
Dexamethasone
50
Melphalan
29
Cyclophosphamide
25
Bortezomib
24
Filgrastim
18
Calcium Dobesilate
18
Peripheral Blood Stem Cell Transplantation
16
daratumumab
13
pomalidomide
10
dexamethasone acetate
8
Lenalidomide
8
fludarabine phosphate
7
ixazomib
6
dexamethasone 21-phosphate
6
Whole-Body Irradiation
6
Mycophenolic Acid
6
venetoclax
5
birtamimab
5
auricularum
5
Thalidomide
5
Granulocyte Colony-Stimulating Factor
5
Cyclosporine
5
Busulfan
5
Radiotherapy
4
Interferon-alpha
4
Etoposide
4
Carboplatin
4
Biopsy
4
sargramostim
3
miridesap
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immunoglobulin Light-chain Amyloidosis
×
talquetamab
×
Clear all
NCT06855121
2025-03-03
NIMMS
St. Olavs Hospital
Recruiting
400 enrolled